Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

作者
Meletios Athanasios Dimopoulos,Dominik Dytfeld,Sebastian Grosicki,Philippe Moreau,Naoki Takezako,Mitsuo Hori,Xavier P Leleu,Richard LeBlanc,Kenshi Suzuki,Marc Steffen Raab,Paul Gerard Guy Richardson,Mihaela Popa McKiver,Ying‐Ming Jou,Suresh G. Shelat,Michael D. H. Robbins,Brian T. Rafferty,Jesús F. San Miguel
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:379 (19): 1811-1822 被引量:543
标识
DOI:10.1056/nejmoa1805762
摘要

BACKGROUND: The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone has been shown to be effective in patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor. METHODS: Patients with multiple myeloma that was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor were randomly assigned to receive elotuzumab plus pomalidomide and dexamethasone (elotuzumab group) or pomalidomide and dexamethasone alone (control group). The primary end point was investigator-assessed progression-free survival. RESULTS: A total of 117 patients were randomly assigned to the elotuzumab group (60 patients) or the control group (57 patients). After a minimum follow-up period of 9.1 months, the median progression-free survival was 10.3 months in the elotuzumab group and 4.7 months in the control group. The hazard ratio for disease progression or death in the elotuzumab group as compared with the control group was 0.54 (95% confidence interval [CI], 0.34 to 0.86; P=0.008). The overall response rate was 53% in the elotuzumab group as compared with 26% in the control group (odds ratio, 3.25; 95% CI, 1.49 to 7.11). The most common grade 3 or 4 adverse events were neutropenia (13% in the elotuzumab group vs. 27% in the control group), anemia (10% vs. 20%), and hyperglycemia (8% vs. 7%). A total of 65% of the patients in each group had infections. Infusion reactions occurred in 3 patients (5%) in the elotuzumab group. CONCLUSIONS: Among patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor had failed, the risk of progression or death was significantly lower among those who received elotuzumab plus pomalidomide and dexamethasone than among those who received pomalidomide plus dexamethasone alone. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-3 ClinicalTrials.gov number, NCT02654132 .).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CaliU发布了新的文献求助10
2秒前
2秒前
努力发AM完成签到,获得积分10
3秒前
清心发布了新的文献求助10
5秒前
6秒前
6秒前
6秒前
乌龙茶完成签到 ,获得积分10
6秒前
6秒前
CJX发布了新的文献求助10
7秒前
车辆学长完成签到 ,获得积分10
7秒前
花样年华发布了新的文献求助10
11秒前
盟主完成签到 ,获得积分10
12秒前
沉静蓉发布了新的文献求助10
12秒前
超表面发布了新的文献求助10
12秒前
annie完成签到 ,获得积分10
14秒前
碧蓝老黑完成签到,获得积分10
14秒前
李健的应助被wm采纳,获得10
14秒前
16秒前
16秒前
16秒前
17秒前
思念变成王年年完成签到,获得积分10
17秒前
19秒前
坚强孤容发布了新的文献求助10
20秒前
LpmxRk发布了新的文献求助10
20秒前
任性子骞完成签到,获得积分10
20秒前
逐徒完成签到,获得积分10
21秒前
甜蜜的大象完成签到 ,获得积分10
21秒前
风起云涌完成签到,获得积分10
22秒前
赵荣吉发布了新的文献求助10
22秒前
哇啦发布了新的文献求助10
23秒前
SOBER发布了新的文献求助10
24秒前
babbo完成签到,获得积分10
25秒前
Arlen完成签到,获得积分10
25秒前
26秒前
SoftwarePrince完成签到 ,获得积分10
29秒前
PP发布了新的文献求助50
30秒前
彬彬完成签到 ,获得积分10
31秒前
英姑的应助被子夜歌采纳,获得30
32秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186806
求助须知:如何正确求助?哪些是违规求助? 9575125
关于积分的说明 21839712
捐赠科研通 7784453
什么是DOI,文献DOI怎么找? 3434839
关于科研通互助平台的介绍 2559245
邀请新用户注册赠送积分活动 2481712